General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Reference |
|---|
| "Cancer cachexia is one of the most prevalent and devastating syndromes associated with advanced cancer." | ( Bruera, E, 1992) |
| "The cause of cancer cachexia is unclear." | ( Illig, KA; Maronian, N; Peacock, JL, 1992) |
| "Cachexia is a common problem in persons infected with the human immunodeficiency virus (HIV)." | ( Murphy, RL; Von Roenn, JH; Wegener, N, 1990) |
| "Anorexia and cachexia are common clinical problems of many patients with advanced cancer." | ( Burch, PA; Ellison, NM; Goldberg, RM; Loprinzi, CL; Michalak, JC, 1990) |
| "Cachexia is often a severe problem in the management of cancer and other illnesses because it adds to the morbidity of the underlying disease and complicates its treatment." | ( Aisner, J; Greco, FA; Moody, M; Tait, N; Tchekmedyian, NS, 1986) |
| "Cancer cachexia is a complex syndrome resulting from metabolic disturbances, mechanical obstacles, and behavioral alterations." | ( Falke, RM, 1985) |
| "Cachexia is a terminal metabolic problem observed in a wide variety of tumours." | ( Lazo, PA, 1985) |
| "Malnutrition and cachexia are major consequences of neoplastic diseases." | ( Garbe, E; Nasca, S; Rigot, JJ; Zeitoun, P, 1980) |
| "Two reasons for cachexia are well known: 1." | ( Büntzel, J; Küttner, K, 1995) |
| "Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients." | ( Loprinzi, CL, 1995) |
| "Cancer cachexia is highly prevalent in patients with advanced cancer." | ( Bruera, E, 1993) |
| "Cachexia is a frequent and devastating complication of advanced cancer." | ( Bruera, E; Vigano, A; Watanabe, S, 1994) |
| "Body wasting (cachexia) is a common feature of cancer and a major cause of morbidity and mortality." | ( Cooper, AL; Morris, ID; Roe, S; Rothwell, NJ, 1996) |
| "Cancer cachexia is a syndrome manifested by a variety of metabolic abnormalities that include depletion of host energy stores." | ( Blumberg, D; Brennan, MF; Burt, M; Harrison, LE; Hochwald, SN; Port, JL, 1996) |
| "Cachexia is common in patients with pancreatic cancer and has been associated with persistent activation of the hepatic acute phase response and increased energy expenditure." | ( Carter, DC; Falconer, JS; Fearon, KC; Plester, CE; Ross, JA; Tisdale, MJ; Wigmore, SJ, 1996) |
| "Cancer cachexia is characterized by loss of lean body mass." | ( Boers, W; de Blaauw, I; Deutz, NE; von Meyenfeldt, MF, 1997) |
| "Anorexia and cachexia are well-known sequelae of cancer that contribute to morbidity and mortality." | ( Hoefnagels, JM; Schols, AM; Simons, JP; ten Velde, GP; Westerterp, KR; Wouters, EF, 1998) |
| "Tumourous cachexia is thus a difficult problem in oncological practice." | ( Vyzula, R, 1997) |
| "Anorexia and cachexia are present in the majority of patients with advanced-stage cancer." | ( Antón, I; Batiste, E; Bestit, I; Blanco, R; Boleda, M; Cirera, L; Giménez-Arnau, JM; Jolis, L; Morales, S; Seguí, MA; Vadell, C, 1998) |
| "Cancer induced cachexia is characterized by complex changes in the intermediary metabolism." | ( de Blaauw, I; Deutz, NE; von Meyenfeldt, MF, 1999) |
| "A new model of cachexia is described in which muscle protein metabolism related to the ubiquitin-proteasome pathway was investigated." | ( Brand, SJ; Coggins, MB; Destree, AT; Dick, LR; Elliott, PJ; Goldberg, AL; Huang, JQ; Lazarus, DD; Mazzola, LM; McCormack, TA; Pierce, JW; Read, MA; Solomon, V; Xu, B, 1999) |
| "Cardiac cachexia is a syndrome of generalised wasting which caries a poor prognosis and is associated with raised plasma concentrations of tumour necrosis factor alpha (TNFalpha)." | ( Dargie, HJ; McMurray, JJ; Morton, JJ; Murdoch, DR; Rooney, E; Shapiro, D, 1999) |
| "Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies." | ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999) |
| "Anorexia and cachexia are diagnosed in more than two-thirds of all cancer patients with advanced disease, and are independent risk factors for morbidity and mortality." | ( Gorter, RW, 1999) |
| "Cancer-induced cachexia is a common manifestation observed in patients with malignancies." | ( Daly, JM; Evoy, D; Fujita, J; Mackrell, P; McCarter, MD; Naama, HA; Rivadeneira, DE, 1999) |
| "Cachexia is frequently associated with advanced or terminal cancer states, but it can also develop early during the course of neoplastic disease." | ( Baccino, FM; Costelli, P, 2000) |
| "Cancer cachexia is a significant problem facing both patients and physicians." | ( Ogawa, M; Yamashita, JI, 2000) |
| "Cachexia is associated with elevated levels of cytokines in cancer and human immunodeficiency virus patients." | ( Levine, DM; Olson, JS; Parker, TS; Schuster, MW; Stevens, MR; Wu, SY; Yeh, SS, 2001) |
| "Cachexia is a syndrome characterized by profound tissue wasting that frequently complicates malignancies." | ( Baccino, FM; Costelli, P; De Tullio, R; Melloni, E, 2001) |
| "Cancer cachexia is characterized by selective depletion of skeletal muscle protein reserves." | ( Drake, JL; Smith, HJ; Tisdale, MJ; Whitehouse, AS, 2001) |
| "Cachexia is a chronic state of negative energy balance and muscle wasting that is a severe complication of cancer and chronic infection." | ( Krauss, S; Lin, J; Lowell, BB; Mootha, VK; Puigserver, P; Rhee, J; Spiegelman, BM; Wu, Z; Yoon, JC; Zhang, CY, 2001) |
| "Cancer-related cachexia is caused by a diverse combination of accelerated protein breakdown and slowed protein synthesis." | ( Abumrad, NN; Barber, A; D'Olimpio, JT; Hourihane, A; May, PE, 2002) |
| "The development of cachexia is commonly seen in many pathological states and is associated with a markedly impaired prognosis." | ( Kalra, PR; Tigas, S, 2002) |
| "Cancer anorexia and cachexia are two distinct syndromes which may have synergistic effects in a patient." | ( Gastell, S; Lochs, H; Ockenga, J; Pirlich, M, 2002) |
| "In contrast, cachexia is a pathological state of malnutrition associated with many infections and chronic diseases, wherein appetite is diminished concomitant with an increase in metabolic rate, and a relative wasting of LBM." | ( Brookhart, G; Butler, AA; Cone, RD; Marks, DL; Turner, R, 2003) |
| "Cachexia is common in patients with advanced cancer and has a direct impact on well-being and mortality." | ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| "Cancer cachexia is a poorly understood syndrome of anorexia, weight loss, and muscle wasting that negatively impacts quality of life and survival in cancer patients." | ( McCarthy, DO, 2003) |
| "Cancer cachexia is characterized by anorexia and intense peripheral catabolism." | ( Curi, R; Fabrício, VE; Fernandes, LC; Fernandez, R; Folador, A; Gobbo-Bordon, D; Hirabara, SM; Jakobi, S; Moretto, KD; Piffar, PM; Pinto, GJ; Rohn, TV; Tchaikovski, O; Tosta, E, 2003) |
| "Cachexia is a common problem in chronic heart failure (CHF) that may be partly mediated by activation of the sympathetic nervous system." | ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "Cachexia is among the most debilitating and life-threatening aspects of cancer and is more common in children and elderly patients." | ( Inui, A, 2004) |
| "Cancer cachexia is a serious and life-treating syndrome that appears in most solid tumor patients." | ( Korniluk, J; Wcisło, G; Wojtuń, S, 2004) |
| "Cachexia is common and is an important risk factor for poor quality of life and increased mortality and morbidity in both adults and children with CKD." | ( Cheung, W; Cone, RD; Mak, RH; Marks, DL, 2005) |
| "Cachexia is metabolic disorder characterized by anorexia, an increased metabolic rate, and loss of lean body mass." | ( Brookhart, GB; Brown, BT; Chen, C; Fleck, BA; Foster, AC; Hesse, A; Hoare, SR; Markison, S; Marks, DL, 2005) |
| "Pain and cachexia are two of the most debilitating aspects of rheumatoid arthritis." | ( Ho, WH; Pons, J; Rosenthal, A; Shelton, DL; Zeller, J, 2005) |
| "Cachexia is among the most debilitating and life-threatening aspects of cancer, and is more common in children and elderly patients." | ( Inui, A, 2005) |
| "Cancer cachexia is a complex, multifactorial syndrome characterised by a critical weight loss, anorexia, asthenia and anaemia." | ( Feheŕ, J; Lelbach, A; Muzes, G, 2004) |
| "Cachexia is common in chronic obstructive pulmonary disease (COPD) and is thought to be linked to an enhanced systemic inflammatory response." | ( Broekhuizen, R; Creutzberg, EC; Grimble, RF; Howell, WM; Schols, AM; Shale, DJ; Wouters, EF, 2005) |
| "Cancer cachexia is a complex metabolic state, characterized by loss of muscle mass and adipose tissue together with anorexia." | ( Catane, R; Epstein, N; Kanety, H; Kaufman, B; Kundel, Y; Oberman, B; Pariente, C; Sadetzki, S; Shimon, I; Wolf, I, 2006) |
| "Cancer cachexia is also associated with poor response to therapy, increased susceptibility to treatment-related adverse events, as well as poor outcome and quality of life." | ( Argilés, JM, 2005) |
| "Cancer cachexia is characterized by skeletal muscle wasting that is mainly supported by hypercatabolism." | ( Argilés, JM; Baccino, FM; Bonelli, G; Bonetto, A; Bossola, M; Busquets, S; Costelli, P; Doglietto, GB; Lopez-Soriano, FJ; Muscaritoli, M; Penna, F; Reffo, P; Rossi Fanelli, F, 2006) |
| "Cancer cachexia is one of the most common manifestations of advanced malignant disease and is frequently associated with decreased survival." | ( Chang, JW; Hsieh, JJ; Shen, YC; Wang, CH; Yeh, KY, 2006) |
| "Cachexia is among the most debilitating and life-threatening aspects of cancer." | ( Inui, A, 2006) |
| "Cancer cachexia is a distressing weight loss syndrome commonly seen in advanced cancer patients." | ( Baughan, C; Dean, T; Dewey, A; Higgins, B; Johnson, I, 2007) |
| "Cachexia is particularly severe in pancreatic cancer and contributes significantly to the quality of life and mortality of these patients." | ( Adrian, TE; Ding, XZ; Melstrom, KA; Melstrom, LG, 2007) |
| "Cachexia is common in chronic heart failure (CHF) and may be due to a combination of reduced appetite, and increased metabolic rate due to immune activation." | ( Clark, AL; Ford, SJ; Parker, JD; Preston, T; Witte, KK, 2008) |
| "Wasting, or cachexia, is a significant, debilitating, and potentially life-threatening complication of HIV infection." | ( Freedland, E; Gelato, M; McNurlan, M, 2007) |
| "Cancer cachexia is associated with decreased survival and poor quality of life." | ( Liao, LM; Liu, KH; Ro, LS; Wu, YL; Yeh, TS, 2008) |
| "Cancer cachexia is a common problem among advanced cancer patients." | ( Berk, L; Hug, E; James, J; Kachnic, L; Mahadevan, A; Samuels, M; Schwartz, A, 2008) |
| "Cancer-related cachexia is an obscure syndrome leading to muscle wasting, reduced physical fitness and quality of life." | ( Bachert, P; Essig, M; Hildebrandt, W; Kauczor, HU; Kinscherf, R; Kopp-Schneider, A; Krakowski-Roosen, H; Krix, M; Schröder, L; Weber, MA, 2009) |
| "Cancer-related cachexia is associated with a loss of muscle volume but not of functionality, which can be a rationale for muscle training." | ( Bachert, P; Essig, M; Hildebrandt, W; Kauczor, HU; Kinscherf, R; Kopp-Schneider, A; Krakowski-Roosen, H; Krix, M; Schröder, L; Weber, MA, 2009) |
| "The hallmarks of cachexia are loss of lean and adipose tissue, anorexia, anemia, memory disturbance, and sickness behavior." | ( Farr, SA; Morley, JE, 2008) |
| "Cachexia is a term used to describe the poor status of a patient suffering from a benign disease (Crohn's disease, chronic heart and kidney failure) as well as from a malignant disease." | ( Bachmann, J; Friess, H; Martignoni, ME, 2008) |
| "Cancer cachexia is associated with marked alterations in skeletal muscle protein metabolism that lead to muscle wasting and, in some cases, death." | ( Dillon, EL; Durham, WJ; Sheffield-Moore, M, 2009) |
| "Cancer cachexia is characterised by metabolic alterations leading to loss of adipose tissue and lean body mass and directly compromises physical performance and the quality of life of cancer patients." | ( Argilés, JM; Arts, K; Faber, J; Gorselink, M; Jansen, H; Kegler, D; Laviano, A; Luiking, Y; van der Beek, EM; van Helvoort, A; van Norren, K, 2009) |
| "Muscle wasting or cachexia is caused by accelerated muscle protein breakdown via the ubiquitin-proteasome complex." | ( Das, T; DeMichele, S; Harvey, KA; Hassan, S; Mukerji, P; Rasool, T; Siddiqui, RA, 2009) |
| "Cancer cachexia is a syndrome of unintentional weight loss that is characterized by wasting of both skeletal muscle and adipose tissue." | ( Asp, ML; Belury, MA; Tian, M; Wendel, AA, 2010) |
| "Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1." | ( Dobs, AS; Zilbermint, MF, 2009) |
| "Cancer cachexia is a significant biochemical event, which is characterized by weight loss, fatigue, and indicative of depletion of skeletal muscle GLN--a hypercatabolic state." | ( Noé, JE, 2009) |
| "Cachexia is characterized by a hypothalamic inappropriate response to the mechanisms controlling energy homeostasis." | ( Dei Cas, A; Muoio, A; Zavaroni, I, 2011) |
| "Cachexia is brought about by the synergistic combination of a dramatic decrease in appetite and an increase in the catabolism of fat and lean body mass." | ( Cheung, WW; Mak, RH; Paik, KH, 2010) |
| "Cachexia is characterized by progressive loss of adipose tissue and skeletal muscle without a concurrent increase in food intake to restore lost tissue stores." | ( Byerley, LO; Clemens, M; Culberson, C; Lee, SH; Lively, MO; Redmann, S, 2010) |
| "Cachexia is characterized by muscle wasting, anorexia, and elevated inflammatory markers." | ( Bruera, E; Dalal, S; Del Fabbro, E; Dev, R; Freer, G; Hui, D; Nooruddin, ZI; Palmer, JL; Roberts, L, 2010) |
| "Cachexia is common in pancreatic cancer and may have an influence on longterm survival but few studies have investigated this in patients with operable tumours." | ( Allen, BJ; Aslani, A; Gill, AJ; Roach, PJ; Smith, RC, 2010) |
| "Cachexia is a multiorganic syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting and inflammation, being often associated with anorexia." | ( Argilés, JM; Busquets, S; Coutinho, J; López-Soriano, FJ; Martínez, R; Orpí, M; Serpe, R; Sirisi, S; Toledo, M, 2010) |
| "Cardiac cachexia is a catabolic state in which adipose tissue atrophy is accompanied by a proinflammatory state." | ( Gonçalves, N; Leite-Moreira, AF; Lourenço, AP; Oliveira, M; Quina-Rodrigues, C; Roncon-Albuquerque, R, 2010) |
| "Cachexia is also associated with systemic inflammation, altered metabolism, and anemia." | ( Baltgalvis, KA; Berger, FG; Carson, JA; Mark Davis, J; Peña, MM; White, JP, 2010) |
| "Cancer cachexia is characterized by muscle and adipose tissue wasting caused partly by chronic, systemic inflammation." | ( Asp, ML; Belury, MA; Kliewer, KL; Stout, MB; Tian, M, 2011) |
| "Cancer cachexia is a dynamic process characterized by a negative energy balance induced by anorexia and hypermetabolism." | ( Bougnoux, P; Chevalier, S; Couet, C; Dumas, JF; Goupille, C; Julienne, CM; Pinault, M; Servais, S, 2011) |
| "Cachexia is a poorly understood syndrome present in already compromised cancer patients, decreasing the quality of life and increasing mortality." | ( Aoyama, H; Camargo, CA; da Silva, ME; da Silva, RA; Gomes-Marcondes, MC; Justo, GZ, 2011) |
| "Oesophageal cancer cachexia is a significant clinical problem, resulting in excessive morbidity and mortality." | ( Cole, AT; Freeman, JG; Khan, ZH; Rennie, MJ; Selby, AL; Wilkes, EA, 2011) |
| "Cancer cachexia is characterized by progressive weight loss with the depletion of adipose tissue and skeletal muscle." | ( Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L, 2011) |
| "Although cancer cachexia is generally regarded as an end-stage irreversible pathological condition, EPA ONS may promote patient compliance with cancer chemotherapy by resolving cachectic condition, and thus may improve survival." | ( Hamamura, K; Miki, C; Miyazaki, M; Nakagawa, M; Nakaya, M, 2011) |
| "Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass." | ( Das, SK; Diwoky, C; Eder, S; Gorkiewicz, G; Guertl, B; Haemmerle, G; Hoefler, G; Kumari, P; Schauer, S; Tamilarasan, KP; Temmel, H; Trauner, M; Vesely, P; Zechner, R; Zimmermann, R, 2011) |
| "Cancer cachexia is characterised by the loss of body mass and directly compromises immune response and the quality of life of cancer patients." | ( Chan, YL; Li, TL; Wang, H; Wu, CJ, 2012) |
| "Cancer-induced cachexia is a complex and poorly understood life-threatening syndrome that is characterized by progressive weight loss due to metabolic alterations, depletion of lipid stores, and severe loss of skeletal muscle protein." | ( Artemov, D; Bhujwalla, ZM; Gadiya, MM; Krishnamachary, B; Nimmagadda, S; Penet, MF; Pomper, MG, 2011) |
| "Cancer cachexia is characterised by a progressive loss of muscle, resulting in functional impairment and shorter survival." | ( Mazurak, VC; Mourtzakis, M; Murphy, RA; Yeung, E, 2011) |
| "Cachexia is characterized by inexorable muscle wasting that significantly affects patient prognosis and increases mortality." | ( Judge, AR; Reed, SA; Sandesara, PB; Senf, SM, 2012) |
| "Cachexia is characterized by severe weight loss, including adipose and muscle wasting, and occurs in a large percentage of cancer patients." | ( Asp, ML; Belury, MA; Kliewer, KL; Tian, M, 2011) |
| "Cancer cachexia is a syndrome of progressive weight loss." | ( Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J, 2011) |
| "Cancer cachexia is a devastating condition leading to loss of function and independence, decreased performance status, decreased quality of life, and poor prognosis." | ( Ceylan, E; Cildag, O; Gulen, ST; Karadag, F; Karul, AB; Kilicarslan, N; Kuman, NK, 2012) |
| "Cachexia is a common co-morbidity in cancer occurring in up to 80% of patients depending on the type of cancer." | ( Adams, V; Anker, SD; Argiles, JM; Doehner, W; Hartman, K; Köhrle, J; Möller, N; Palus, S; Ruis, SB; Springer, J; Tschirner, A; von Haehling, S; Wirth, EK, 2012) |
| "Cancer cachexia is characterized by hypoalbuminemia and with the hepatic production of acute-phase proteins in response to malignant growth." | ( Kagawa, Y; Kawakami, J; Naito, T; Ohnishi, K; Tashiro, M; Yamamoto, K, 2012) |
| "Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life." | ( Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J, 2013) |
| "Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven." | ( Baracos, VE; Bekaii-Saab, T; Doyle, LA; Ghosh, S; Prado, CM; Sawyer, MB; Shrestha, S, 2012) |
| "Cancer cachexia is a multidimensional syndrome characterised by wasting, loss of weight, loss of appetite, metabolic alterations, fatigue and reduced performance status." | ( Cantwell, M; Cardwell, CR; Donnelly, M; Mills, M; Murray, LJ; Reid, J, 2012) |
| "Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle." | ( Fearon, KC; Glass, DJ; Guttridge, DC, 2012) |
| "Cancer cachexia is a complex and dynamic process characterized by a negative energy balance induced by anorexia and hypermetabolism which leads to a drastic loss in body weight that aggravate prognosis of cancer patients." | ( Couet, C; Dumas, JF; Peyta, L; Servais, S, 2013) |
| "Cancer cachexia is a complex catabolic state in patients with a malignancy, associated with increased morbidity and mortality." | ( Buijs, N; Houdijk, AP; Luttikhold, J; van Leeuwen, PA, 2012) |
| "Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress." | ( Hinch, E; Lewandowski, PA; Martin, P; Sullivan-Gunn, M; Vaughan, VC, 2012) |
| "Cachexia is a wasting condition that manifests in several types of cancer, and the main characteristic is the profound loss of muscle mass." | ( Argilés, JM; Busquets, S; Fontes-Oliveira, CC; García, A; Inês Genovese, M; López-Soriano, FJ; Olivan, M; Orpí, M; Paz Aylwin, M; Penna, F; Sette, A; Silva, AP; Sirisi, S; Toledo, M, 2013) |
| "Cachexia is a state of involuntary weight loss common to many chronic diseases." | ( Letilovic, T; Mestric, ZF; Perkov, S; Vrhovac, R, 2013) |
| "Cachexia is a multiorganic syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting and inflammation, being often associated with anorexia." | ( Anguera, A; Argilés, JM; Stemmler, B, 2013) |
| "Cancer cachexia is an unmet medical need and our data suggest that use of enobosarm might lead to improvements in lean body mass, without the toxic effects associated with androgens and progestational agents." | ( Boccia, RV; Croot, CC; Dalton, JT; Dobs, AS; Gabrail, NY; Hancock, ML; Johnston, MA; Steiner, MS, 2013) |
| "Rheumatoid cachexia is associated with rheumatoid arthritis and it increases mortality and morbidity." | ( Fernández-Galaz, C; Gómez-SanMiguel, AB; López-Calderón, A; López-Menduiña, M; Martín, AI; Nieto-Bona, MP; Villanúa, MÁ, 2013) |
| "Cachexia is a wasting condition that manifests in several types of cancer." | ( Ametller, E; Argilés, JM; Busquets, S; Demuth, J; Figueras, M; Fontes-Oliveira, CC; Fuster, G; Isfort, RJ; López-Soriano, FJ; Olivan, M; Qu, X; Stevens, P; Toledo, M; Varbanov, A; Wang, F, 2014) |
| "Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths." | ( Anker, SD; Doehner, W; Hartman, K; Springer, J; Tschirner, A; von Haehling, S, 2013) |
| "Cachexia is a serious complication of many chronic diseases, such as congestive heart failure (CHF) and chronic kidney disease (CKD)." | ( Delafontaine, P; Galvez, S; Higashi, Y; Mitch, WE; Sukhanov, S; Tabony, AM; Yoshida, T, 2013) |
| "Cancer cachexia is a life-threatening condition characterized by involuntary body weight loss and skeletal muscle wasting." | ( Jo, E; Khamoui, AV; Kim, JS; Lee, WJ; Park, BS, 2013) |
| "Cancer-associated cachexia is characterized, among other symptoms, by a dramatic loss of both muscle and fat." | ( Argilés, JM; Busquets, S; Costelli, P; López-Soriano, FJ; Massa, D; Penna, F; Pin, F; Toledo, M, 2013) |
| "Anorexia-cachexia is a common and severe cancer-related complication but the underlying mechanisms are largely unknown." | ( Blomqvist, A; Ihnatko, R; Post, C, 2013) |
| "Cancer cachexia is the syndrome of weight loss, loss of appetite, and wasting of skeletal muscle and adipose tissue experienced by many individuals with cancer." | ( Honors, MA; Kinzig, KP, 2014) |
| "Cachexia is a complex metabolic syndrome characterized by skeletal muscle and adipose tissue loss and is frequently associated with emaciation, anorexia, systemic inflammation, and metabolic dysfunction." | ( Klein, GL; Petschow, BW; Shaw, AL; Weaver, E, 2013) |
| "Cancer cachexia is thought to be the cause of >20% of cancer related deaths." | ( Anker, SD; Beadle, J; Coats, AJ; Doehner, W; Elkina, Y; Hartmann, K; Mayer, U; Palus, S; Springer, J; Tschirner, A; von Haehling, S, 2013) |
| "Cachexia is a limiting prognostic factor for patient survival and health care costs." | ( Bachmann, J; Friedrich, O; Martignoni, ME; Stumpf, VI; Taskin, S; Weber, C, 2014) |
| "Cachexia is defined as a multifactorial syndrome that is associated with anorexia, weight loss and increased catabolism, with increased morbidity and mortality." | ( Dobs, A; Srinath, R, 2014) |
| "Cachexia is a relevant comorbid condition of chronic diseases including cancer." | ( Barreiro, E; Chacon-Cabrera, A; de Kier Joffé, ED; Diament, MJ; Fermoselle, C; Mateu-Jimenez, M; Sandri, M; Urtreger, AJ, 2014) |
| "Pre-cachexia and cachexia are observed in patients with cancer, chronic heart failure or liver cirrhosis." | ( Biolo, G; Cederholm, T; Muscaritoli, M, 2014) |
| "Cancer cachexia is a metabolic syndrome featuring many alterations typical of type 2 diabetes (T2D)." | ( Chevalier, S; Farsijani, S, 2014) |
| "Cancer cachexia is regulated by proinflammatory cytokines such as interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor- α (TNF- α)." | ( Cho, SG; Choi, YK; Jun, CY; Jung, KY; Ko, SG; Park, JH; Shin, YC; Woo, SM; Yun, YJ, 2014) |
| "Cancer cachexia is a syndrome of weight loss that results from the selective depletion of skeletal muscle mass and contributes significantly to cancer morbidity and mortality." | ( Agarwal, A; Braun, TP; Grossberg, AJ; Levasseur, PR; Marks, DL; Szumowski, M; Zhu, X, 2014) |
| "Cancer cachexia is a multifactorial syndrome characterized by progressive loss of weight and muscle atrophy." | ( Azuma, T; Chayahara, N; Fujiwara, Y; Imamura, Y; Kiyota, N; Kobayashi, T; Minami, H; Mukohara, T; Nishiumi, S; Toyoda, M; Yoshida, M, 2014) |
| "Cachexia is a multifactorial syndrome, characterized by the loss of skeletal muscle mass and not fully reversible by nutritional support." | ( de Barsy, M; Frateur, L; Gruson, D; Lause, P; Loumaye, A; Nachit, M; Thissen, JP; Trefois, P; van Maanen, A, 2015) |
| "Cachexia is a multifactorial syndrome characterized by profound involuntary weight loss, fat depletion, skeletal muscle wasting, and asthenia; all symptoms are not entirely attributable to inadequate nutritional intake." | ( Andreotti, S; Batista, ML; Beluzi, M; Farmer, SR; Franco, FO; Henriques, FS; Knobl, P; Lima, FB; Neves, RX; Peres, SB; Santos, KB; Seelaender, M; Sertié, RA; Shida, CS, 2015) |
| "Cancer cachexia is a debilitating paraneoplastic wasting syndrome characterized by skeletal muscle depletion and unintentional weight loss." | ( Isaac, ST; Polly, P; Tan, TC, 2016) |
| "Sarcopenia and cachexia are muscle wasting syndromes associated with aging and with many chronic diseases, such as congestive heart failure (CHF), diabetes, cancer, chronic obstructive pulmonary disease and chronic kidney disease (CKD)." | ( Delafontaine, P; Yoshida, T, 2015) |
| "Cancer cachexia is characterized by muscle wasting caused partly by systemic inflammation." | ( Nakamura, K; Sasayama, A; Takahashi, T; Yamaji, T, 2015) |
| "Cancer cachexia is a debilitating condition characterized by a combination of anorexia, muscle wasting, weight loss, and malnutrition." | ( Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Boutajangout, A; Daley, D; Deutsch, M; Greco, SH; Levie, E; Mahmood, SK; Malik, H; Miller, G; Mohaimin, T; Ochi, A; Pachter, HL; Pansari, M; Rendon, M; Rokosh, R; Tippens, D; Tomkötter, L; Torres-Hernandez, A; Vahle, AK; Wisniewski, T; Zambirinis, C, 2015) |
| "Cachexia is the result of complex metabolic alterations which cause morbidity and mortality in patients with advanced cancers including undifferentiated (anaplastic) thyroid carcinoma (ATC)." | ( Hu, N; Husain, A; Nucera, C; Sadow, PM, 2016) |
| "Cancer cachexia is a severe inflammatory metabolic syndrome accounting for fatigue, an impairment of normal activities and, eventually, death." | ( Gramignano, G; Macciò, A; Madeddu, C; Mantovani, G, 2015) |
| "Cancer cachexia is a multi-organ, multifactorial and often irreversible syndrome affecting many patients with cancer." | ( Criscitiello, C; Curigliano, G; Di Leo, M; Esposito, A; Gelao, L; Liuzzi, R; Locatelli, M; Massaro, M; Milani, A; Minchella, I; Pravettoni, G, 2015) |
| "Cachexia is one of the most common manifestations in advanced cancer patients, but too often it remains under- recognized and under-treated." | ( Meriggi, F, 2015) |
| "Cancer cachexia is a debilitating condition that impacts patient morbidity, mortality, and quality of life and for which effective therapies are lacking." | ( Bekaii-Saab, T; Bloomston, M; Chen, CS; Frankhouser, DE; Guttridge, DC; He, WA; Hsu, EC; Kulp, SK; Lai, IL; Lesinski, GB; Marcucci, G; Mo, X; Tseng, YC; Yan, PS, 2015) |
| "Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis." | ( Chaika, NV; Dasgupta, A; Goode, G; Gunda, V; King, R; Mehla, K; Mishra, A; Nagarajan, S; Rai, I; Shukla, SK; Singh, PK; Souchek, J; Vernucci, E; Yu, F, 2015) |
| "Cachexia is a significant problem in patients with cancer." | ( de Souza, SR; Fracaro, L; Frez, FC; Guarnier, FA; Linden, DR; Martins, HA; Silva, BC; Vicentini, GE; Zanoni, JN, 2016) |
| "Cancer cachexia is a multifactorial syndrome that includes muscle wasting and inflammation." | ( Bindels, LB; Cani, PD; Claus, SP; Delzenne, NM; Grangette, C; Le Roy, CI; Martinez, I; Neyrinck, AM; Pot, B; Walter, J, 2016) |
| "Cancer cachexia is a syndrome characterized by loss of skeletal muscle mass, inflammation, anorexia and anemia, contributing to patient fatigue and reduced quality of life." | ( Argilés, JM; Busquets, S; Camperi, A; Costelli, P; Lopez-Soriano, FJ; Penna, F; Pin, F; Toledo, M, 2015) |
| "Cachexia is a metabolic disorder characterised by muscle wasting, diminished response to anti-cancer treatments and poor quality of life." | ( Gagnon, B; MacDonald, N; Murphy, J; Penafuerte, CA; Sirois, J; Tremblay, ML, 2016) |
| "Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis." | ( Aoe, K; Atagi, S; Eguchi, K; Kagamu, H; Katakami, N; Komura, N; Koyama, A; Saito, H; Takayama, K; Takiguchi, Y; Yokoyama, T; Yoshimori, K, 2016) |
| "Cancer cachexia is a syndrome characterized by weight loss (WL) and sarcopenia." | ( Alongi, F; Di Paola, G; Fersino, S; Fiorentino, A; Giaj Levra, N; Mazzola, R; Ricchetti, F; Ruggieri, R, 2016) |
| "Cachexia is a devastating muscle-wasting syndrome that occurs in patients who have chronic diseases." | ( Chen, S; Chua, C; Fukawa, T; Ho, YS; Huang, D; Jun-Hao, ET; Kanayama, HO; Lai, JH; Li, Z; Lim, WJ; Mak, SY; Min-Wen, JC; Mohan, RE; Ong, HS; Ong, P; Qian, CN; Shyh-Chang, N; Tan, IB; Tan, KK; Teh, BT; Wang, RR; Yan-Jiang, BC, 2016) |
| "Cachexia is a devastating syndrome that causes morbidity and mortality in a large number of patients with cancer." | ( Bohnert, KR; Gallot, YS; Hindi, SM; Kumar, A; Sato, S; Xiong, G, 2016) |
| "Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle." | ( Baracos, VE; Bathe, OF; Cervo, L; Giavazzi, R; Lecker, SH; Martinelli, GB; Olivari, D; Ottoboni, L; Piccirillo, R; Re Cecconi, AD; Resovi, A; Stretch, C; Talamini, L, 2016) |
| "Cachexia is defined by increased fatigue and loss of muscle function resulting from muscle and fat depletion." | ( Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA, 2016) |
| "Cachexia is a life-threatening wasting syndrome lacking effective treatment, which arises in many cancer patients." | ( Chen, JL; Colgan, TD; Gregorevic, P; Hagg, A; Harrison, CA; Qian, H; Walton, KL; Watt, MJ, 2016) |
| "Cancer cachexia is a complex wasting condition characterized by chronic inflammation, disrupted energy metabolism, and severe muscle wasting." | ( Carson, JA; Enos, RT; Hardee, JP; Murphy, EA; Narsale, AA; Puppa, MJ; VanderVeen, BN, 2016) |
| "Cancer cachexia is a multifactorial syndrome affecting the skeletal muscle." | ( Cheng, G; Jie, L; Jin, L; Jin-Lu, H; Li-Li, W; Peng-Guo, C; Quan-Jun, Y; Run, G; Yan, H; Yong-Long, H, 2017) |
| "Cachexia is one of the most important causes of cancer-related death." | ( Canevarolo, R; Gomes-Marcondes, MC; Lubaczeuski, C; Luiz, AC; Soares, RF; Viana, LR; Zeri, AC, 2016) |
| "Cancer cachexia is characterized by inflammation, loss of skeletal muscle and adipose tissue mass, and functional impairment." | ( Chekachak, S; Chenari, J; Mahdavi, M; Molanouri Shamsi, M; Quinn, LS; Ranjbar, K; Soudi, S; Yazdi, MH, 2017) |
| "Since cachexia is known to produce severe inflammation, malnutrition and inhibition of albumin gene expression, we have also monitored the total proteins, albumin, TNF-α and IL-6 levels in arthritic rats and its modulation by agmatine." | ( Chopde, CT; Gawande, DY; Kotagale, NR; Taksande, BG; Umekar, MJ, 2017) |
| "Sarcopenia and cachexia are muscle-wasting syndromes associated with aging and with many chronic diseases such as congestive heart failure, diabetes, cancer, chronic obstructive pulmonary disease, and renal failure." | ( Delafontaine, P; Yoshida, T, 2016) |
| "Cancer cachexia is a complex disorder characterized by inflammatory responses, and it is associated with poor performance status and high mortality rate of cancer patients." | ( Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Ye, CY; Zhang, DC; Zhu, L, 2017) |
| "Cancer cachexia is a multifactorial syndrome that dramatically decreases survival." | ( Alves, MJ; Azevedo, FF; Camargo, RG; Cavallaro, DA; De Alcântara, PS; Figuerêdo, RG; Junior, ML; Lima, JD; Matos-Neto, E; Neto, NI; Otoch, JP; Radloff, K; Riccardi, DM; Seelaender, M, 2017) |
| "Cachexia is a wasting condition associated with cancer types and, at the same time, is a serious and dose-limiting side effect of cancer chemotherapy." | ( Ben Haj Salah, K; Bresciani, E; Caloiero, R; Camerino, GM; Coluccia, M; Conte, D; Conte, E; De Bellis, M; De Luca, A; Fehrentz, JA; Fonzino, A; Giustino, A; Liantonio, A; Lograno, MD; Mariggiò, MA; Martinez, J; Mele, A; Pierno, S; Rana, F; Rizzi, L; Torsello, A; Tricarico, D, 2017) |
| "Cancer cachexia is a progressive wasting disease resulting in significant effects on the quality of life and high mortality." | ( Bicer, S; Devine, RD; Reiser, PJ; Wold, LE, 2017) |
| "Cachexia is the main cause of mortality in advanced cancer patients." | ( Bazotte, RB; Carpinelli, ÂR; da Silva, FG; de Fatima Silva, F; de Morais, H; de Souza, HM; Graciano, MFR; Martins, MIL; Mazucco, TL; Silva, MO, 2017) |
| "Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life." | ( Abernethy, A; Currow, D; Fearon, KC; Friend, J; Milanowski, J; Temel, JS, 2017) |
| "Cachexia is defined as a complex metabolic syndrome associated with underlying illness that is characterized by the loss of body weight consisting of muscle and fat mass wasting." | ( Anker, M; Anker, SD; Doehner, W; Ishida, J; Saitoh, M; Springer, J; von Haehling, S, 2017) |
| "Cancer cachexia is often present in patients with advanced malignant tumors, and the subsequent body weight reduction results in poor quality of life." | ( Guo, D; Qiao, Z; Tang, H; Wang, C; Wang, Q, 2017) |
| "Cancer cachexia is characterised by involuntary weight loss associated with systemic inflammation and metabolic changes." | ( Cruz, B; Gomes-Marcondes, MCC; Oliveira, A, 2017) |
| "Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function." | ( Balstad, TR; Bye, A; Fallon, M; Fayers, P; Fearon, K; Johns, N; Kaasa, S; Laird, BJA; Pettersen, CH; Solheim, TS; Stene, GB, 2017) |
| "Cachexia is a complex metabolic and behavioural syndrome lacking effective therapies." | ( Burfeind, KG; Krasnow, SM; Levasseur, PR; Marks, DL; Michaelis, KA; Morgan, TK; Zhu, X, 2017) |
| "Cancer cachexia is a multifactorial metabolic syndrome characterized by marked loss of adipose tissue and skeletal muscle." | ( Alcântara, PSM; Batista, ML; Lira, FS; Oller do Nascimento, CM; Otoch, JP; Oyama, LM; Seelaender, M; Silvério, R, 2017) |
| "Cancer cachexia is characterized by muscle depletion and exercise intolerance caused by an imbalance between protein synthesis and degradation and by impaired myogenesis." | ( Chiandotto, S; Costelli, P; Ferraro, E; Gorini, S; Molinari, F; Musarò, A; Penna, F; Pin, F; Pisu, S; Pontecorvo, L; Rizzuto, E; Rosano, G, 2017) |
| "Cardiac cachexia is a form of serious illness that results with terminal stage of heart failure." | ( Fan, QX; Ke, CQ; Li, B; Xue, SZ; Zhang, HX; Zhang, M; Zhao, JX, 2017) |
| "Cancer cachexia is a devastating metabolic syndrome characterized by systemic inflammation and massive muscle and adipose tissue wasting." | ( Caretti, G; Costelli, P; Dae Ko, K; Fenizia, C; Filippakopoulos, P; Fittipaldi, R; Hatakeyama, S; Merigliano, S; Pierobon, ES; Pin, F; Sandri, M; Sartorelli, V; Sartori, R; Segatto, M; Sperti, C; Zanchettin, G; Zare, H, 2017) |
| "Cachexia is a metabolic wasting disorder characterized by progressive weight loss, muscle atrophy, fatigue, weakness, and appetite loss." | ( Cano, R; Juan, R; Kandil, D; McGlacken, GP; Pastor-Cavada, E; Schellekens, H; Shaban, H; Shanahan, R; Torres-Fuentes, C, 2018) |
| "Cachexia is associated with poor prognosis and accelerated death in patients with cancer, yet its underlying mechanisms remain poorly understood." | ( Acharyya, S; Biswas, AK; Borczuk, A; Coker, C; Davuluri, RV; Fukada, T; Grandgenett, PM; Hebert, D; Hojyo, S; Hollingsworth, MA; Jain, R; Jenkitkasemwong, S; Kandpal, M; Knutson, MD; Lόpez-Pintado, S; Ma, W; Tanji, K; Wang, G, 2018) |
| "Cancer cachexia is unintended bodyweight loss occurring with cancer, and skeletal muscle wasting is a critical predictor of negative outcomes in the cancer patient." | ( Carson, JA; Counts, BR; Montalvo, RN, 2018) |
| "Cachexia is a devastating complication of cancer and an important cause of morbidity and mortality and can have a great effect on quality of life, and sense of self-esteem." | ( Gaidhane, A; Gaidhane, S; Khatib, MN; Quazi, ZS, 2018) |
| "Cachexia is a complex metabolic condition associated with progressive body weight loss, wasting of skeletal muscle mass and decrease in muscle strength." | ( Langen, RCJ; Theys, J; van de Worp, WRPH; van Helvoort, A, 2018) |
| "Cancer cachexia is a severe, debilitating condition characterized by progressive body wasting associated with remarkable loss of skeletal muscle weight." | ( Fukada, SI; Hinohara, A; Inaba, S; Tachibana, M; Tsujikawa, K, 2018) |
| "Cancer cachexia is a multilayered syndrome consisting of the interaction between tumor cells and the host, at times modulated by the pharmacologic treatments used for tumor control." | ( Cella, D; Currow, DC; Maddocks, M; Muscaritoli, M, 2018) |
| "Cachexia is a multisystem syndrome characterized by weight loss, anorexia, loss of muscle mass, systemic inflammation, insulin resistance, and functional decline." | ( Advani, PG; Advani, SM; Jafri, SH; VonVille, HM, 2018) |
| "Cancer cachexia is a metabolic disorder involving perturbed energy balance and altered mitochondrial function." | ( Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F, 2019) |
| "Cancer cachexia is a metabolic disease characterized by a negative energy balance associated with systemic weight loss and poor quality of life." | ( Hsu, MY; Porporato, PE; Wyart, E, 2019) |
| "Cardiac cachexia is a syndrome of progressive skeletal muscle and fat loss affecting a significant number of congestive heart failure patients." | ( Ahmed, MM; Kamel, A; Kramer, J; Rolfe, M, 2019) |
| "Cachexia is more prevalent in patients with this cancer and has a negative effect on response to chemotherapy and radiotherapy." | ( Akhtari, J; Ebrahimzadeh, MA; Golpour, M; Hosseini-Khah, Z; Rafiei, A; Tahaghoghi-Hajghorbani, S, 2019) |
| "Cancer cachexia is a systemic wasting syndrome characterized by anorexia and loss of body weight." | ( Hisaka, A; Kurebayashi, N; Miyano, K; Nonaka, M; Sakurai, T; Sato, H; Uezono, Y; Uzu, M; Yanagihara, K, 2019) |
| "Cachexia is a paraneoplastic syndrome related with poor prognosis." | ( Alcantara, P; Alves, MJ; Cabral, FJ; de Castro, G; de Matos-Neto, EM; Felipe-Silva, AS; Ferro, ES; Figueredo, RG; Laviano, A; Lima, JDCC; Morais, MRPT; Otoch, JP; Pinto, NI; Seelaender, M; Simoes, E; Tokeshi, F; Zorn, TMT, 2019) |
| "Cancer cachexia is a multifactorial metabolic syndrome that affects ∼50%-80% of cancer patients, and no effective therapy for cancer cachexia is presently available." | ( Fan, M; Guo, XD; Li, N; Liu, X; Shen, Q; Zhang, WL; Zhang, XW; Zhang, Z, 2020) |
| "Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer." | ( Baba, H; Choda, Y; Furuse, J; Furuya, K; Hamauchi, S; Higashiguchi, T; Komura, N; Munemoto, Y; Muro, K; Naito, T; Oyama, S; Takano, T; Takayama, K; Takeuchi, M; Takiguchi, T; Tamura, K, 2019) |
| "Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality." | ( Christensen, H; Faber, J; Johansen, ML; Kistorp, C; Rasmussen, J; Refsgaard Holm, M; Schou, M, 2019) |
| "Cachexia is the primary cause of death in approximately 30% of cancer patients, and is often evidenced in ovarian cancer patients." | ( Kakar, SS; Straughn, AR, 2019) |
| "Cancer cachexia is a complicated disorder of extreme, progressive skeletal muscle wasting." | ( Daou, HN, 2020) |
| "Cancer cachexia is a severe condition that leads to the death of advanced cancer patients, and approximately 50~80% of cancer patients have cancer cachexia." | ( Ci, Y; Han, M; Li, H; Lu, S; Zhang, J; Zhang, Y, 2020) |
| "Cachexia is common in malignant mesothelioma (MM); half of patients have malnutrition and low skeletal muscle mass." | ( Bowyer, S; Brims, F; Chih, HJ; Creaney, J; Fyfe, K; Hawkins, F; Hoon, SN; Jeffery, E; Nowak, A; Peddle-McIntyre, CJ, 2020) |
| "Cachexia is a major characteristic of multiple non-malignant diseases, advanced and metastatic cancers and it is highly prevalent in pancreatic cancer, affecting almost 70-80% of the patients." | ( Antoniadou, D; Karamouzis, MV; Koustas, E; Papadimitropoulou, A; Papavassiliou, AG; Poulia, KA; Sarantis, P, 2020) |
| "Cancer cachexia is a complex and multifactorial syndrome that influences about 50-80% of cancer patients and may lead to 20% of cancer deaths and muscle atrophy is the key characteristic of the syndrome." | ( Chen, SZ; Ge, Z; Li, Y; Liu, D; Shang, Y, 2020) |
| "Cachexia is a common multifactorial syndrome in the advanced stages of cancer and accounts for approximately 20-30% of all cancer-related fatalities." | ( Kakar, SS; Kelm, NQ; Straughn, AR, 2020) |
| "Cancer cachexia is not only a problem in itself, but it also reduces the effectiveness of treatments and deteriorates quality of life." | ( Choi, BM; Han, YH; Hong, SH; Jeon, HD; Kee, JY; Mun, JG; Yoon, DH, 2020) |
| "Cancer cachexia is a wasting disorder characterised by specific skeletal muscle and adipose tissue loss." | ( Masi, T; Patel, BM, 2021) |
| "Cancer cachexia is characterized by reductions in peripheral lean muscle mass." | ( Berent, TE; Dorschner, JM; Jatoi, A; Kumar, R; Kunz, HE; Lanza, IR; Meyer, T; Wang, X, 2020) |
| "Cancer cachexia is a complex multifaceted syndrome involving functional impairment, changes in body composition, and nutritional disorders." | ( Fonseca, GWPD; von Haehling, S, 2021) |
| "Cancer cachexia is a multifactorial debilitating syndrome that directly accounts for more than 20% of cancer deaths while there is no effective therapeutic approach for treatment of cancer cachexia." | ( Gu, X; Li, Y; Liu, X; Lu, S; Ma, M; Shen, Q; Zhang, L; Zhang, W; Zhang, X, 2021) |
| "Muscle wasting and cachexia are prominent comorbidities in cancer." | ( Barreiro, E; Duran, X; López-Postigo, A; Mateu, J; Penedo-Vázquez, A, 2021) |
| "The term "cachexia" is derived from the Greek words kakos (bad) and hexis (habit)." | ( Asai, A; Fukunishi, S; Goto, M; Higuchi, K; Nishiguchi, S; Nishikawa, H, 2021) |
| "Cancer cachexia is characterized by the loss of skeletal muscle resulting in functional impairment, reduced quality of life and mortality." | ( Angelotti, A; Belury, MA; Cole, RM; Ni, A; Nishikawa, Y; Snoke, DB; Vodovotz, Y, 2021) |
| "Cancer cachexia is associated with many types of tumors and is characterized by a combination of anorexia, loss of body weight, catabolic alterations, and systemic inflammation." | ( Léopold, P; Santabárbara-Ruiz, P, 2021) |
| "Cancer cachexia is mainly characterized by wasting of skeletal muscles and fat and body weight loss, along with severe complications of major organs like liver, heart, brain and bone." | ( Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D, 2022) |
| "Cancer cachexia is a serious metabolic disorder syndrome that is responsible for the deaths of approximately 30% of patients with cancer, but effective drugs for cancer cachexia are still lacking." | ( Kuang, JX; Li, YW; Liu, X; Miao, CX; Shen, Q; Zhang, WL; Zhang, XW, 2022) |
| "Cachexia is a muscle wasting syndrome occurring in many advanced cancer patients." | ( Law, ML; Metzger, JM, 2021) |
| "Cancer cachexia is a syndrome characterized by anorexia and decreased body weight." | ( Atagi, S; Furuse, J; Higashiguchi, T; Kojima, T; Matano, Y; Minato, K; Mizukami, T; Morishima, E; Muro, K; Naito, T; Takayama, K; Takiguchi, T; Tamura, K; Tanaka, K; Uchino, J, 2022) |
| "Cachexia is a wasting syndrome characterized by devastating skeletal muscle atrophy that dramatically increases mortality in various diseases, most notably in cancer patients with a penetrance of up to 80%." | ( Bindels, LB; Geninatti Crich, S; Hirsch, E; Hsu, MY; Lauria, A; Martini, M; Mazzone, M; Menga, A; Mezzanotte, M; Mina, E; Penna, F; Pezzini, C; Pierobon, ES; Porporato, PE; Prenen, H; Rausch, V; Roetto, A; Sandri, M; Sartori, R; Wyart, E, 2022) |
| "Cachexia is frequent, deadly, and untreatable for patients with pancreatic ductal adenocarcinoma (PDAC)." | ( Koniaris, LG; Liu, S; Liu, Y; Narasimhan, A; Shahda, S; Silverman, LM; Wan, J; Young, AR; Zhong, X; Zimmers, TA, 2022) |
| "Cancer cachexia is a systemic paraneoplastic phenomenon involving multiple organs, including the liver." | ( Ge, YZ; Li, XR; Ruan, GT; Shi, HP; Song, CH; Song, MM; Zhang, KP; Zhang, Q; Zhang, X; Zhang, XW, 2022) |
| "Cancer cachexia is a multifactorial disease that causes continuous skeletal muscle wasting." | ( Fukasawa, K; Hanada, K; Hayashi, Y; Hinata, H; Hirai, H; Imai, S; Itoh, F; Ohfusa, R; Takayama, K, 2022) |
| "Cachexia is a metabolic syndrome consisting of massive loss of muscle mass and function that has a severe impact on the quality of life and survival of cancer patients." | ( Balsano, R; Barone, M; Cavazzoni, A; Comandatore, A; Garajovà, I; Giovannetti, E; Kruize, Z; Lunardi, M; Morelli, L; Piccirillo, R; Re Cecconi, AD; Tiseo, M; van Zuylen, L; Wilmink, H, 2022) |
| "Cachexia is characterized by progressive weight loss accompanied by the loss of specific skeletal muscle and adipose tissue." | ( Li, L; Lin, K; Pu, W; Song, S; Su, Z; Wang, H; Wang, R; Wang, Y; Wazir, J; Wei, L; Zhao, C, 2022) |
| "Cachexia is a systemic disease associated with several pathologies, including cancer, that leads to excessive weight loss due to enhanced protein degradation." | ( Fiaschi, T; Gamberi, T; Garella, R; Magherini, F; Mannelli, M; Squecco, R, 2022) |
| "Cancer cachexia is a metabolic syndrome that is characterized by progressive loss of skeletal muscle mass, and effective therapeutics have yet to be developed." | ( Chen, JY; Chen, LL; Guo, C; Wang, Y; Xia, LY; Xu, WH; Zhang, JP, 2023) |
| "Cancer cachexia is a metabolic syndrome that is characterized by progressive loss of skeletal muscle mass, and effective therapeutics have yet to be developed." | ( Chen, JY; Chen, LL; Guo, C; Wang, Y; Xia, LY; Xu, WH; Zhang, JP, 2023) |
| "Cancer cachexia is a metabolic disease affecting multiple organs and characterized by loss adipose and muscle tissues." | ( Heo, SC; Jung, S; Kim, Y; Park, G; Shin, H, 2023) |
| "Cancer cachexia is a metabolic disease affecting multiple organs and characterized by loss adipose and muscle tissues." | ( Heo, SC; Jung, S; Kim, Y; Park, G; Shin, H, 2023) |
| "Stroke cachexia is associated with prolonged inflammation, muscle loss, poor prognosis, and early death of stroke patients." | ( Joshi, M; Patel, BM; Shah, D; Shah, J, 2023) |
| "Cachexia is a multifactorial debilitating syndrome that is responsible for 22% of mortality among cancer patients, and there are no effective therapeutic agents available." | ( Li, L; Lin, K; Pu, W; Song, S; Su, Z; Wang, H; Wang, R; Wazir, J; Wei, L; Zhao, C; Zhao, Q, 2023) |
| "Cancer cachexia is associated with reduced body weight, appetite and quality of life (QOL) with no approved treatments." | ( Ammer, N; Anderson, LJ; Garcia, JM; Graf, SA; Herodes, M; Marcelli, M; Salas, R; Schur, EA; Shober, S, 2023) |
| "Cachexia is a debilitating wasting syndrome and highly prevalent comorbidity in cancer patients." | ( Beltrà, M; Corrà, S; Fornelli, C; Hsu, MY; Hulmi, JJ; Kivelä, R; Moletta, L; Penna, F; Pirinen, E; Pöllänen, N; Porporato, PE; Sandri, M; Sartori, R; Tonttila, K; Viscomi, C; Zampieri, S, 2023) |
| "Cachexia is a common cancer complication and is associated with weight loss and anorexia." | ( Inoue, M; Ishida, H; Kawashiri, T; Kobayashi, D; Kudamatsu, H; Mine, K; Mori, K; Shimazoe, T; Tsuchiya, T; Uchida, M, 2023) |
| "Cancer cachexia is a multi-organ syndrome with unintentional weight loss, sarcopenia, and systemic inflammation." | ( Grundmann, O; Yoon, SL, 2023) |
| "Cancer-associated cachexia is a multi-organ weight loss syndrome, especially with a wasting disorder of adipose tissue and skeletal muscle." | ( Chen, Y; Cheng, S; Hu, S; Hu, Y; Li, J; Li, M; Li, X; Liu, L; Liu, Y; Xu, Y; Yan, W; Zhang, X; Zhou, H, 2023) |
| "Cancer cachexia is a multifactorial syndrome that interferes with treatment and reduces the quality of life and survival of patients." | ( Agulló-Ortuño, MT; Flández, M; Grau, M; López-Martín, JA; Mancebo, E; Núñez Sobrino, JA; Paz-Ares, L, 2023) |
| "Cancer cachexia is characterized by weight loss and skeletal muscle wasting." | ( Cheng, D; Chi, M; Ding, J; Guo, C; Hao, J; Huang, J; Sun, X; Wang, Y; Xin, B; Xincai, Z; Xu, R; Yang, Q; Yuan, T; Zhang, H; Zhang, J; Zheng, S; Zhou, S; Zhu, X, 2023) |
| "Cachexia is a major cause of morbidity and mortality in individuals with cancer and is characterized by weight loss due to adipose and muscle tissue wasting." | ( Alsina-Sanchis, E; Berriel Diaz, M; Billeter, AT; Borggrefe, T; De Angelis Rigotti, F; Fischer, A; Fleming, T; Friedrich, T; Giaimo, BD; Hasan, SS; Herzig, S; Kaltenbach, S; Korff, T; Mogler, C; Moll, I; Morgenstern, J; Mülfarth, R; Müller-Stich, BP; Nickel, F; Rodriguez-Vita, J; Rohm, M; Schenk, D; Sprinzak, D; Taylor, J; Uhl, L; Wiedmann, L, 2023) |
| "Cancer cachexia is a complex metabolic disorder accounting for ~20% of cancer-related deaths, yet its metabolic landscape remains unexplored." | ( Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Matsuo, K; Mishiro-Sato, E; Muro, K; Narita, Y; Nozawa, K; Ogata, T; Oze, I; Satoh, K; Soga, T; Taketo, MM, 2023) |
| "Cancer cachexia is a systemic metabolic disorder syndrome characterized by severe wasting of muscle and adipose tissues while is lack of effective therapeutic approaches." | ( Cheng, C; Dan, J; Gu, X; Liu, X; Pan, X; Wei, K; Zhang, G; Zhang, X; Zhao, Y, 2023) |